Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Rebecca J. Loomis"'
Autor:
Patrick O. Byrne, Brian E. Fisher, David R. Ambrozak, Elizabeth G. Blade, Yaroslav Tsybovsky, Barney S. Graham, Jason S. McLellan, Rebecca J. Loomis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Henipaviruses such as Nipah virus (NiV) cause severe encephalitis with high fatality rates in humans. NiV fusion (F) glycoprotein is a key target of the host immune response. Here, Byrne et al. isolate ten neutralizing antibodies against NiV prefusio
Externí odkaz:
https://doaj.org/article/496b231ac59e4e758d2a99f1801b371b
Autor:
Rebecca J. Loomis, Anthony T. DiPiazza, Samantha Falcone, Tracy J. Ruckwardt, Kaitlyn M. Morabito, Olubukola M. Abiona, Lauren A. Chang, Ria T. Caringal, Vladimir Presnyak, Elisabeth Narayanan, Yaroslav Tsybovsky, Deepika Nair, Geoffrey B. Hutchinson, Guillaume B. E. Stewart-Jones, Lisa A. Kueltzo, Sunny Himansu, John R. Mascola, Andrea Carfi, Barney S. Graham
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from bats-to-humans with almost annual regional outbreaks characterized by documented human-to-human transmission and high fatality rates. Currently, no vaccine aga
Externí odkaz:
https://doaj.org/article/1645dea2614f43f6baad4345b571338b
Autor:
Rebecca J. Loomis, Guillaume B. E. Stewart-Jones, Yaroslav Tsybovsky, Ria T. Caringal, Kaitlyn M. Morabito, Jason S. McLellan, Amy L. Chamberlain, Sean T. Nugent, Geoffrey B. Hutchinson, Lisa A. Kueltzo, John R. Mascola, Barney S. Graham
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Licensed vaccines or therapeutics are rarely available for pathogens with epidemic or pandemic potential. Developing interventions for specific pathogens and defining generalizable approaches for related pathogens is a global priority and inherent to
Externí odkaz:
https://doaj.org/article/a1bbbff82f3d4c11bf226a9b4c218342
Autor:
Rebecca J. Loomis, Philip R. Johnson
Publikováno v:
Vaccines, Vol 3, Iss 2, Pp 429-447 (2015)
Vaccination has proven to be an invaluable means of preventing infectious diseases by reducing both incidence of disease and mortality. However, vaccines have not been effectively developed for many diseases including HIV-1, hepatitis C virus (HCV),
Externí odkaz:
https://doaj.org/article/92171dda8a0a4fc6b628079a4af277a5
Autor:
Patrick O. Byrne, Brian E. Fisher, David R. Ambrozak, Elizabeth G. Blade, Yaroslav Tsybovsky, Barney S. Graham, Jason S. McLellan, Rebecca J. Loomis
Nipah virus (NiV) is a pathogenic paramyxovirus that causes fatal encephalitis in humans. Two envelope glycoproteins, the attachment protein (G/RBP) and fusion protein (F), facilitate entry into host cells. Due to its vital role, NiV F presents an at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0001673fcd30972889720e8c29325c1f
https://doi.org/10.1101/2022.06.13.495706
https://doi.org/10.1101/2022.06.13.495706
Autor:
Andrea Carfi, John R. Mascola, Nancy J. Sullivan, Barney S. Graham, Kizzmekia S. Corbett, Mahnaz Minai, Olubukola M. Abiona, Tracy J. Ruckwardt, Anne P. Werner, Gabriela S. Alvarado, Ralph S. Baric, Anthony T. DiPiazza, Ian N. Moore, Lauren A. Chang, Darin K. Edwards, Emily Phung, Juan I. Moliva, Sarah R. Leist, Kenneth H. Dinnon, Seyhan Boyoglu-Barnum, Bianca M. Nagata, Rebecca J. Loomis, Kaitlyn M. Morabito, Alexandra Schäfer, Kevin W. Bock
Publikováno v:
Immunity
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndrome (SARS) and MERS coronavirus vaccines. We used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d47b9df60b9bfa751735256f0928c5
http://europepmc.org/articles/PMC8249710
http://europepmc.org/articles/PMC8249710
Autor:
James D. Chappell, Elisabeth Narayanan, Kaitlyn M. Morabito, Alexandra Schäfer, Laura J. Stevens, Yi Zhang, Stephen D. Schmidt, Kevin W. Bock, Isabella Renzi, Ian N. Moore, Dario Garcia-Dominguez, Catherine Liu, Kizzmekia S. Corbett, Christine A. Shaw, Cynthia T. Ziwawo, Mark R. Denison, Lauren A. Chang, Lingshu Wang, Sunny Himansu, Mihir Metkar, Guillaume Stewart-Jones, Seyhan Boyoglu-Barnum, Daniel Wrapp, Kendra Gully, Geoffrey B. Hutchinson, Kwanyee Leung, Wing-Pui Kong, Emily Phung, Eun Sung Yang, Mahnaz Minai, Rebecca A. Gillespie, Angela Woods, Jason S. McLellan, Sarah R. Leist, Mark K. Louder, Sayda Elbashir, David R. Martinez, Darin K. Edwards, Bianca M. Nagata, Kenneth H. Dinnon, John R. Mascola, Martha Nason, Hamilton Bennett, Rebecca J. Loomis, Ande West, Andrea Carfi, Olubukola M. Abiona, Barney S. Graham, Anthony T. DiPiazza, Wei Shi, Ralph S. Baric, Nicole A. Doria-Rose, Kapil Bahl, Nedim Emil Altaras, Nianshuang Wang, Tracy J. Ruckwardt, Ethan J. Fritch, Vladimir Presnyak, LingZhi Ma
Publikováno v:
bioRxiv
Nature
Nature
Summary A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc8dc81b2d35d6bf33db624622f8357
https://europepmc.org/articles/PMC7301911/
https://europepmc.org/articles/PMC7301911/
Autor:
Guillaume Stewart-Jones, Lisa A. Kueltzo, Kaitlyn M. Morabito, John R. Mascola, Rebecca J. Loomis, Amy L. Chamberlain, Jason S. McLellan, Barney S. Graham, Geoffrey B. Hutchinson, Sean Nugent, Yaroslav Tsybovsky, Ria T. Caringal
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology
Licensed vaccines or therapeutics are rarely available for pathogens with epidemic or pandemic potential. Developing interventions for specific pathogens and defining generalizable approaches for related pathogens is a global priority and inherent to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43759e33489085b7ba577f2dcabeacf
https://www.frontiersin.org/article/10.3389/fimmu.2020.00842/full
https://www.frontiersin.org/article/10.3389/fimmu.2020.00842/full
Autor:
Eun Sung Yang, Cuiping Liu, Nicole A. Doria-Rose, Dario Garcia-Dominguez, Hamilton Bennett, Nianshuang Wang, Kapil Bahl, Nedim Emil Altaras, Kaitlyn M. Morabito, Alexandra Schäfer, Kevin W. Bock, John R. Mascola, Kai Wu, Guillaume Stewart-Jones, Ethan J. Fritch, Kizzmekia S. Corbett, Kwanyee Leung, Mahnaz Minai, Ling Zhi Ma, Andrea Carfi, Christine A. Shaw, Barney S. Graham, Mark K. Louder, Anthony T. DiPiazza, Wing Pui Kong, Stephen D. Schmidt, Yi Zhang, Sayda Elbashir, Ande West, Gabriela S. Alvarado, Wei Shi, Isabella Renzi, Ralph S. Baric, Elisabeth Narayanan, Mihir Metkar, Bianca M. Nagata, Tracy J. Ruckwardt, Rebecca J. Loomis, Martha Nason, Darin K. Edwards, Cynthia T. Ziwawo, Sunny Himansu, Emily Phung, Seyhan Boyoglu-Barnum, Laura J. Stevens, Kendra Gully, Carole Henry, Olubukola M. Abiona, Angela Woods, Lauren A. Chang, Sarah R. Leist, Geoffrey B. Hutchinson, Daniel Wrapp, Kenneth H. Dinnon, James D. Chappell, Lingshu Wang, Vlad Presnyak, Rebecca A. Gillespie, Jason S. McLellan, David R. Martinez, Ian N. Moore, Mark R. Denison
Publikováno v:
Nature
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb9dfcf84b0b1edbdebf8300c5160b8
Autor:
Ingelise J. Gordon, Mark G. Lewis, Gabriela S. Alvarado, Ralph S. Baric, Martin R. Gaudinski, Laura Novik, Kwanyee Leung, Jack Greenhouse, Tammy Putman-Taylor, Katelyn Steingrebe, Seyhan Boyoglu-Barnum, Kathryn E. Foulds, Tracey-Ann Campbell, Tongqing Zhou, Wei Shi, I-Ting Teng, Peter D. Kwong, Juan I. Moliva, Laurent Pessaint, Christina Yap, Mahnaz Minai, Olubukola M. Abiona, Nancy J. Sullivan, Nadesh N Nji, Kaitlyn M. Morabito, Amarendra Pegu, Stephen D. Schmidt, Julie E. Ledgerwood, Sunny Himansu, Barbara J. Flynn, Shanai Browne, Anne P. Werner, Darin K. Edwards, Eun Sung Yang, Kevin W. Bock, Joseph R. Francica, Yi Zhang, Dillon R. Flebbe, Kizzmekia S. Corbett, Nicole A. Doria-Rose, Ian N. Moore, Andrea Carfi, Amanda Strasbaugh, Mario Roederer, Guillaume Stewart-Jones, Emily Phung, Robert A. Seder, Tracy J. Ruckwardt, Adrian B. McDermott, Anthony Cook, Sarah O’Connell, Alicia T. Widge, Wing-Pui Kong, Mark K. Louder, Martha Nason, Bob C. Lin, David R. Martinez, Alex Van Ry, Alan Dodson, Evan Lamb, Britta Flach, Bianca M. Nagata, Rebecca J. Loomis, John R. Mascola, Barney S. Graham, John-Paul Todd, Sijy O'Dell, Lauren A. Chang, Naomi Douek, Lingshu Wang, Rebecca A. Gillespie, Hanne Leth Andersen, Amy T. Noe, Mitzi M. Donaldson
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background: Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1beae7dcc7af2b55333337512c240b